3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
High-risk Leukemias
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
Temozolomide
69
Radiotherapy
30
Bevacizumab
24
Carboplatin
13
pembrolizumab
12
Radiation
11
Carmustine
8
Irinotecan
7
temsirolimus
6
Surgical Procedures, Operative
6
Radiosurgery
6
Erlotinib Hydrochloride
6
atezolizumab
5
Vorinostat
5
Sirolimus
5
Radiotherapy, Intensity-Modulated
5
Nivolumab
5
Lomustine
5
Everolimus
5
fludarabine
4
Radiotherapy, Conformal
4
Magnetic Resonance Spectroscopy
4
Cyclophosphamide
4
Aminolevulinic Acid
4
tipifarnib
3
Sorafenib
3
Paclitaxel
3
IL13-PE38
3
Granulocyte-Macrophage Colony-Stimulating Factor
3
Gemcitabine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Glioblastoma
×
Interleukin-15
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled